Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Synature Ltd

15 Nov 2005 07:03

Angle PLC15 November 2005 For immediate release 15 November 2005 ANGLE plc ("ANGLE") SENIOR APPOINTMENTS AND VENTURE UPDATE ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce two senior appointments at its venture company, SynatureLtd. Founded earlier this year, Synature Ltd (formerly known as Customiser Group Ltd)provides psychological profiling tools that engage the consumer, deliveringinsight into individual attitudes and consumer preferences complementingtraditional demographic models. Based in Guildford Surrey, Synature Ltd is oneof ANGLE's eight venture companies. Dr. John Woods joins Synature Ltd as Chief Executive Officer. Previously founderand Chief Executive of Site Intelligence Ltd, one of the UK's most successfulweb analytics companies, John has worked with clients such as Argos, Expedia,SAP and Lloyds TSB. Dr. Woods has 15 years' experience in commercialisation and marketing ofadvanced software technologies. He holds a doctorate from Jesus College, Oxfordand an MBA. Commenting on his appointment, Dr. Woods said "I am delighted to be joining the Synature team at this exciting stage in thecompany's development. Marketing departments have a growing appetite forenhanced profiling and targeting of online and offline customers. Synature'sunique intellectual property offers a compelling way to meet that need.Moreover, ANGLE provides Synature with a supportive environment in which thatcompelling intellectual property can be rapidly and successfully commercialised." Professor William J. Fitzgerald joins Synature Ltd as a consultant technicaladvisor. He is Professor of Applied Statistics and Signal Processing and Headof the Signal Processing and Communications Laboratory at the University ofCambridge. He consults for a number of successful high technology companies inboth the UK and USA. Professor Fitzgerald commented: "Synature's consumer profiling techniques demonstrate the real world businessbenefits that can be obtained from state-of-the-art data analysis and patternrecognition. I am excited to be part of the team and to be ensuring thatSynature's clients receive maximum insight and maximum value from theapplication of our technologies." Stephen Bence, Director of New Ventures at ANGLE, added: "These two key appointments complement Synature's existing founding team andprovide the company with additional commercial and technical expertise. We areexcited about the opportunity that Synature's unique intellectual propertyrepresents." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Synature Ltd 08701 909550John Woods, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com Synature Ltd is an ANGLE Technology group company formed to commercialiseintellectual property acquired in 2005 from Customiser Ltd. Synature'sintellectual property provides unique ways to profile consumers in terms oftheir underlying preferences. The resulting profiles allow fine-grainedconsumer segmentation that complements traditional demographics. Synature'stechniques can be applied both online and offline. Further information can be found on www.synature.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.